All In MedTech

Device Trial Radar · NCT07756242

Pharmacokinetic Study of Therapeutic Plasma Exchange

A Phase 1 Pharmacokinetic Study of Therapeutic Plasma Exchange for Severe Immune-Related Adverse Events From Immune Checkpoint Inhibitors

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Nov 2026

Primary completion

Nov 2027

Study completion Feb 2028

Sponsor

Lead sponsor
University of ChicagoAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 10, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterize the pharmacokinetics of one or more ICIs during and after TPE/PLEX in patients with severe irAEs.

Conditions

  • Immune-related Adverse Event

Interventions

  • Spectra Optia Apheresis SystemDevice

    Therapeutic plasma exchange (using the Spectra Optia Apheresis System) will be done according to standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in circulating ICI concentration during and after TPE/PLEXTime frame: Baseline to Day 90

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The University of Chicago

    Chicago, Illinois

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.